Evaluating Custom Synthesis Partners and Key Starting Materials
Applying ICH Q11 starting-material rules, technology transfer protocols, and IP safeguards when contracting custom chemical synthesis and CDMO scale-up.
Defining Key Starting Materials (KSMs) Under ICH Q11
Selecting where GMP manufacturing officially begins—the API Starting Material or Key Starting Material (KSM)—is one of the most consequential regulatory decisions in custom synthesis. Under ICH Q11, a starting material must contribute a significant structural fragment to the final API, possess well-defined chemical properties, and leave enough downstream GMP purification steps to purge impurities effectively.
Regulators frequently reject proposed starting materials that sit only one or two synthetic steps away from the final API, forcing costly retrospective re-validation of upstream intermediate plants under full ICH Q7 GMP. Aligning KSM boundaries with ICH Q11 Q&A principles early prevents late-stage filing delays.
- Confirm KSM incorporation as a significant structural fragment of the API.
- Verify multiple independent chemical steps occur between the KSM and final API.
- Assess whether the KSM is a commercially available chemical or custom-synthesized.
- Document full impurity carry-over and fate-and-purge studies from the KSM forward.
Evaluating CDMO Technical Capabilities and Reactor Compatibility
Custom synthesis projects fail most often during laboratory-to-kilo-lab or pilot-scale technology transfer when reaction exotherms, filtration bottlenecks, or cryogenic conditions exceed plant equipment limits. Evaluating a Contract Development and Manufacturing Organization (CDMO) requires matching reaction chemistry directly to installed reactor metallurgy and utility ranges.
Process safety data—including Differential Scanning Calorimetry (DSC) and reaction calorimetry—must accompany every synthesis transfer package before scaling energetic reagents, hydrogenations, or hazardous organometallic couplings.
Technology Transfer Protocols and Process Validation Stages
Structured technology transfer follows a documented Quality by Design (QbD) roadmap linking Process Design (Stage 1), Process Performance Qualification (Stage 2), and Continued Process Verification (Stage 3). Defining Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs) ensures batch reproducibility across sites.
During scale-up, analytical teams validate in-process controls (IPCs) to monitor reaction completion, chiral integrity, and residual catalyst removal prior to final crystallization and drying.
- Execute a formal Tech Transfer Gap Assessment covering solvents, glass-lined vs Hastelloy vessels.
- Define Proven Acceptable Ranges (PARs) for temperature, stoichiometry, and quench rates.
- Validate analytical methods for starting materials, intermediates, and in-process checks.
- Complete three consecutive Process Performance Qualification (PPQ) batches at target scale.
Protecting Intellectual Property and Commercial Scale Economics
Custom synthesis agreements must clearly allocate ownership of background IP, process improvements developed during route scouting, and regulatory master-file rights. Ambiguous IP clauses can lock a sponsor into a single CDMO if the partner patents an improved crystallization or catalyst system.
Separating early route-scouting fee-for-service contracts from commercial supply agreements preserves negotiating flexibility as batch sizes expand from 10-kilogram pilot runs to multi-ton production.
ICH Q11 Custom Synthesis & KSM Boundary Benchmarks
| Supply Tier | Regulatory Status | Purity & Impurity Control | CDMO Audit Requirement |
|---|---|---|---|
| Basic Raw Material / Reagent | Non-GMP chemical supply | ACS / industrial grade + vendor CoA | Paper screening + incoming ID testing |
| Non-GMP Regulatory KSM | Pre-GMP (ICH Q11 justified) | Defined spec + mutagenic impurity screen | Quality systems audit (ISO 9001 / Q11) |
| GMP Intermediate (Late Step) | Full ICH Q7 GMP mandatory | Validated methods + full batch record | Full on-site ICH Q7 GMP audit |
| Crude API (Prior to Recryst.) | Full ICH Q7 GMP mandatory | Controlled polymorph & solvent limits | Full on-site ICH Q7 + PAI readiness |
| Final Isolated API | Full ICH Q7 + DMF/CEP | Complete compendial & ICH M7 release | Full ICH Q7 audit + QTA + CoA release |
Boundaries follow ICH Q11 (Development and Manufacture of Drug Substances) and ICH Q11 Q&A guidance.
Worked Illustration: Evaluating a Proposed Key Starting Material (KSM)
In this worked illustration, assume a CDMO proposes a 4-step synthesis for a new kinase inhibitor API and wants to designate Intermediate X (Step 3) as the regulatory KSM to save GMP costs.
- Step 1 (Check Step Count): Intermediate X sits only one bond-forming coupling and one recrystallization away from the final API, raising high regulatory rejection risk.
- Step 2 (Assess Commercial Availability): Intermediate X is custom-made exclusively for this drug and is not a broadly traded commodity chemical.
- Step 3 (Shift KSM Boundary Upstream): Designate the commercially traded boronic ester at Step 1 instead, placing Steps 2, 3, and 4 inside the GMP synthesis boundary.
- Step 4 (Impurity Purge Validation): Execute purge studies across Steps 2–4 demonstrating >1,000-fold clearance of Step 1 trace impurities.
Worked Illustration Summary: Moving the KSM boundary upstream from Step 3 to Step 1 aligns with ICH Q11 expectations and prevents regulatory inspection delays during NDA review.
CDMO & Custom Synthesis Due Diligence Checklist
- Justify all Key Starting Materials against ICH Q11 and ICH Q11 Q&A criteria.
- Verify CDMO reactor capacities, temperature/pressure ratings, and containment levels.
- Complete DSC and reaction calorimetry hazard testing before pilot scale-up.
- Establish clear CQA, CPP, and analytical transfer protocols in the tech transfer plan.
- Confirm IP ownership of improved routes, polymorphs, and process inventions.
- Audit late-step intermediate vendors under full ICH Q7 GMP requirements.
Frequently Asked Questions
What is the biggest mistake sponsors make when selecting a Key Starting Material?
Designating a complex, custom-made late intermediate only 1–2 steps from the final API as the KSM, which FDA and EMA frequently reject during filing review.
Must a KSM manufacturer be ICH Q7 GMP certified?
Formal ICH Q7 GMP begins after the designated starting material enters the API synthesis, though buyers still audit KSM vendors for quality systems, change control, and impurity consistency.
What should be included in a chemical technology transfer package?
Batch synthesis recipes, raw material specifications, process safety/calorimetry data, in-process analytical methods, impurity profiles, and waste-stream handling details.
When is Process Performance Qualification (PPQ) conducted?
PPQ batches are executed at commercial scale—typically three consecutive compliant lots—after process design is locked and before commercial launch.
Primary Standards & Regulatory References
- ICH Q11: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological Entities)
- ICH Q11 Questions and Answers: Selection and Justification of Starting Materials
- FDA Guidance for Industry: Process Validation — General Principles and Practices